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GlycoExpress™: A toolbox for the high yield production of 
glycooptimized fully human biopharmaceuticals in perfusion bioreactors 
at different scales  
S. Kreye, R. Stahn, K. Nawrath, A. Danielczyk and S. Goletz 
Glycotope GmbH, Berlin, Germany  
steffen.kreye@glycotope.com 
Background 
Glycosylation is one of the major post-translational modifications of biotherapeutics important for bioactivity, bioavailability, immunogenicity and patient coverage. By establishment of the 
GlycoExpress™ toolbox (GEX™) we have generated a set of glycoengineered human cell lines for the high yield production of fully human glycoproteins to optimize the glycosylation of antibodies 
and non-antibody biotherapeutics for improvement of the clinical efficacy and side effects. The system is biotechnologically superior in quality, reproducibility and yield compared to other including 
conventional production systems. All four clinical products derived from GlycoExpress™ cells are produced using a perfusion bioreactor system in order to assure highest possible product quality and 
reproducibility combined with high yield production. 
Experimental approach: 
GlycoExpress™ cells producing mAb were cultivated with perfusion bioreactor systems applying 
different cell retention mechanisms such as centrifugation (centritech™) or alternating tangential 
flow (ATF™) filtration at different scales. A 10 mL based down-scale perfusion system with good 
comparability to larger scale cultivations was established. Growth, product yield and product 
quality, especially glycosylation, are evaluated during the cultivations. 
Conclusion 
The GlycoExpress™ technology is a platform for the high yield production of recombinant proteins 
with fully human glycosylation. In combination with perfusion culture cells are kept in the optimal 
growing and production phase over the production process which leads to highly stable product 
quality allowing a flexible duration of the run in one batch size in combination with stable high 
productivity of the cells over time. Furthermore the product qualities produced in different scales 
ranging from 10 mL to 1000 L cultivation vessels are highly comparable. A small scale perfusion 
system was successfully established for GEX and CHO cells with good comparability to 1L ATF 
perfusion cultures.  
































GlycoExpress™: A toolbox of glycoengineered proprietary 









Development of downscale ambr perfusion system 
For the efficient development of a perfusion process a good downscale system is necessary to 
evaluate different clones at an early stage as well as to perform process optimization with a 
system as close as possible to the final production scale. Here, we describe first data of small scale 
perfusion system based on sedimentation in a micro-bioreactor system. For cell retention , stirring 
and pH/DO control is stopped allowing cells to settle. After a specific time cell free harvest is 
removed from the top of the bioreactor and replaced by fresh medium. This procedure is then 
repeated several times to enable a perfusion rate of up to 2 reactor volumes a day. All steps are 










40 minutes are  sufficient to achieve a separation efficiency of >99% for GEX and CHO cells. 










Down scale cultivations are in very good agreement with 1 L ATF cultivations. Viability for 
sedimentation based perfusion is higher than for ATF cultivations. Up to eight times of stirring  and 
pH-DO control stop for  40  minutes does not negatively impact growth and viability. Glycan 











The sedimentation based ambr perfusion is applicable to CHO as well. CHO cells  show good 
growth and high viability independent of the aeration strategy  for a non-optimized perfusion 



















































Mab2-GEX in MabExpress 
Production of IgG using GlycoExpressTM 
GlycoexpressTM is well suited to produce monoclonal antibodies (mAbs) in large quantities with 







Independent of the applied cell retention mechanism, GlycoExpress™ cells show robust growth  














No measurable differences in product quality between batches, batch sizes, reactor sizes, process 
control strategies, DSP scales and production site. Glycan structure analysis was performed by 































GMP, 100 L; n=12
GMP, 200 L; n=6
R&D, 0.01L; n=1
Non-GMP, 1000L SUB; n=1





























R&D, 1 L, n=2
non-GMP, 10 L, n=1
GMP, 100 L, n=3
GMP, 200 L, n=7
































GMP, 100 L; n=12
GMP, 200 L; n=6
R&D, 0.01L; n=1
Non-GMP, 1000L SUB; n=1





























R&D, 1 L, n=2
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Mab2 Glycosylation in MabExpress
R&D, 0.01L; n=1
Cell Concentration





























































































Mab3-GEX in MabExpress 









































































GlycoExpress™ cells produce only high 
class human glycans. Glycosylation can 
have a huge impact on the bioactivity 
of recombinant proteins. For example,  
defucosylated antibodies as well as 
bisecting N-acetylglucosamine 
structures are known to increase ADCC 
activity and terminal sialic acids  have 
an anti-inflammatory function and 
decreased cytoxicity. The figure on the 
right shows typical N-glycans for 
mAbs. Standard analytics at Glycotope 
cover other PTMs such oxidation, 
lysine clipping or deamidation as well. 
High productivity for glycooptimized 
products:  
(total yield per 40 day perfusion run per L 
bioreactor volume, R&D data)  
~15-20 g/L IgG antibody 
~10-15 g/L IgA antibody 
~ 3 g/L IgM antibody 
~0.2 - 2g/L for complex glycoproteins 
 ( e.g.FSH, bloodfactors, hormones etc.) 
Hybrid process:  
continuous USP, discontinuous DSP 
USP conditions 
- optimized for ATFTM or CentritechTM  
- perfusion length: approx. 40 -100 day 
Mab (Optimized for high ADCC) 
produced in MabExpress 
Mab1-GEX in MabExpress 
(Optimized for high ADCC 
low Fucose, high Galactose) 
Mab3-GEX (Optimized for high 






















































































non-sparged (n=2) sparged (n=2)



































































































































































Mab2-GEX in MabExpress 
